Overexpression of HER2 has been observed in various adenocarcinomas, spanning breast cancer, bladder cancer, ovarian cancer, endometrial cancer, cervical cancer, lung cancer, esophageal cancer, and gastric cancer. This evidence concerns the gene ERBB2 and urinary bladder carcinoma.